Overview and Benefits of Port Delivery Device with Ranibizumab

Opinion
Video

Panelists discuss how the port delivery system (PDS) with ranibizumab represents a paradigm shift in neovascular AMD treatment by utilizing a surgically implanted refillable device that provides continuous medication delivery for 6 months, offering patients a preferred alternative to frequent intravitreal injections while ensuring consistent therapeutic levels.

Video content above is prompted by the following:

  • Can you provide an overview of the port delivery device with ranibizumab approved for treating neovascular AMD?
  • How does the device function?
  • What are the benefits of using the port delivery device with ranibizumab?
  • Certainty of 6 months of continuous anti-VEGF delivery
  • Patients in clinical trials prefer PDS over intravitreal injections
Recent Videos
2 experts in this video
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Vikas Chopra at AAO 2024: Advancements in MIGS are transforming patient care
AAO 2024: Bonnie An Henderson, MD, talks about advancing medical education with AI, robotics, and diverse learning methods
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Related Content
© 2025 MJH Life Sciences

All rights reserved.